Monitor FDA acceptance decision in Q4 2026, if the sNDA is accepted with Priority Review, the target action date would be approximately six months later. Approval would open a new indication for XPOVIO, but the binary risk of non-acceptance or FDA disagreement on the surrogate endpoint remains high given the company's $42M market cap and going concern warning.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 31 $2.06entry
- T+1 · 3mo ago −10.19%α −9.51% · $1.85
- T+5 · 2mo ago −16.50%α −16.36% · $1.72
- T+20 · 7w ago −41.50%α −41.32% · $1.21
- T+54 · todayOpen
- T+60 · in 7d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis, based on Phase 3 SENTRY trial data showing a promising overall survival signal. Priority Review was requested, which could yield a six-month review cycle. FDA acceptance and review timeline decisions are expected in Q4 2026.
Key Facts
- sNDA submitted for XPOVIO (selinexor) + ruxolitinib in myelofibrosis under Accelerated Approval pathway
- Priority Review requested; if granted, review period would be approximately six months
- FDA decision on sNDA filing acceptance and review timelines expected in Q4 2026
- Submission based on Phase 3 SENTRY trial data with a positive benefit-risk profile and overall survival signal
- Accelerated Approval requires FDA agreement that SVR35 is a reasonably likely surrogate endpoint for overall survival
- Company plans to use long-term overall survival data from SENTRY to support conversion to traditional approval
Financial Impact
No specific financial figures provided; potential expansion of XPOVIO addressable market into myelofibrosis if approved. Company has going concern risk noted in forward-looking statements.
Risk Factors
- FDA may not accept the sNDA or may deny Priority Review
- FDA may not agree that SVR35 is a reasonably likely surrogate endpoint for overall survival
- Company has expressed substantial doubt about its ability to continue as a going concern
- Long-term overall survival data from SENTRY may not verify clinical benefit, preventing conversion to traditional approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-375495 |
| Document: 0001193125-26-375495-index-headers.html | 0001193125-26-375495 |
| Document: 0001193125-26-375495-index.html | 0001193125-26-375495 |
| Document: 0001193125-26-375495.txt | 0001193125-26-375495 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers